News and Intelligence : RoseRyan Intelligence
The dream team is always coming up with better solutions for sticky finance problems. Here you’ll find useful insights on emerging growth challenges, building a solid finance infrastructure, tricky regulations and other issues we geek out on.
11.09.11
M&A: Get what you bargained for
It’s easy to get distracted by a hot acquisition’s sleek exterior and miss the engine that’s about to blow. Think the lawyers will protect you? Think again—they do legal due diligence. Every aspect of an acquisition’s operations merits your prying eyes. This report tells you which tires to kick—and how hard.
06.23.11
Are you ready for convergence?
Long-awaited (dreaded?) global accounting standards are finally upon us—and they’ll affect almost every aspect of your business, from compensation to leasing decisions to information systems. This report gives you the lowdown on current proposals, continuing debates and smart moves to make right now.
05.11.11
Ace your IPO filing
The market’s right and your business is in prime IPO shape—you’re ready to file. Now it’s just a matter of some paperwork, right? Alas, no. Plenty of details can still trip you up. This guide, part two of our two-part IPO series, lays out an S-1 filing process that will deliver you safely to your road show.
04.26.11
IPO in your future?
Many a promising company has missed their IPO runway because they tripped over finance messes. In most cases, the catastrophe could have been avoided with some savvy advance work. Get insight into the most common hazards—and how to deal with them—in this guide.
03.24.11
Debt demystified
If you’ve decided to take the plunge into debt financing to fuel your company’s growth, this guide’s for you. Geared mainly toward private technology companies, it covers debt structures and terms, what to watch out for, evaluating loan proposals and building a strong lender relationship.
02.17.11
Debt is good (sometimes)
You’ve already begged. You can’t steal. Is it time to borrow? Our guide, geared to private technology companies, helps you see whether debt financing is right for you, what your loan options are and what types of lenders are a good match.
01.11.11
Biotech tax credit top issues: Q&A with RoseRyan
Last fall, quite a few Bay Area biotech companies got big grant or tax credit awards from the federal Qualifying Therapeutic Discovery Project program. In this article for BayBio, RoseRyan explains how recipients can make sure they get the proper credit and their accounting passes audit muster.
12.27.10
Revenue recognition: 8 key questions for life sciences companies
Rev rec isn’t a hot topic at most biotech companies, but rule changes and the marvelous complexity of life sciences revenue arrangements make it essential that executives at least know what questions to ask. RoseRyan guru Maureen Earley tells you what to ask in this BayBio guest column.
10.12.10
Make a match made in heaven
Think your company might want to be acquired? Hoping to grow through strategic acquisitions? M&A activity is heating up again—make sure you’re ready when that unbeatable offer or amazing buy comes along. Our guide outlines smart moves for both buyers and sellers—and why it pays to understand how the other half thinks.
08.04.10
Rev rec’s apples and oranges
The final challenge in adopting the new rev rec rules is dealing with the hangover of reporting hassles in comparing pre- and post-adoption data. Our guide helps you avoid headaches by walking you through options for providing financial reports that will satisfy executives, investors and analysts alike.
07.14.10
Does rev rec compute?
You may be willing (well, obligated) to comply with the new Financial Accounting Standards Board (FASB) guidelines, but your accounting system is likely to take a dive when it gets hit with the relative selling price method affected companies are required to use. Sorry we don’t have better news, but we can offer you our guide to evaluating system capabilities and finding a solution.
06.24.10
Priced to sell
What’s the market value of something that’s never sold on its own? That’s not a riddle—it’s a question many companies have to answer, and soon. New revenue recognition rules require you to estimate the selling price of each piece in a product bundle—whether it’s sold on its own or not. This guide provides a framework for tackling the challenge.
06.02.10
OMG! Rev rec is coming!
If you’re on a calendar year, you’re under orders to adopt new rules on revenue recognition by January 1, 2011. Don’t freak out—just prepare. This guide will help you start addressing such existential questions as: Are they talking about us? Is it our lucky day? Is the price right? And is it better to look forward or back?
04.14.10
Blueprint for growth: building a smart finance infrastructure
No start-up or growth company wants to spend money on finance. But you know what really hurts? A mysterious cash leak. Or an equity accounting problem that derails your IPO. Or having to spend a lot of money to clean up your accounting so you can pass an audit. This guide outlines a cost-effective strategy to prevent such finance meltdowns.
03.17.10
Roadmap for growth: business information systems that grow with you
Business information systems need to be just the right size—not too big or too small, too simple or too complex—so you can avoid expensive messes, keep a handle on costs and be ready for all kinds of opportunities. This article, the fourth in a series in BayBioNotes, helps you suss out needs for all stages of growth.
12.14.09
Roadmap for growth: right resources, right systems, right time
Outside service providers and consultants can be invaluable and cost-effective—especially if you’re an emerging company. To help you save money (and who doesn’t want that?), RoseRyan provides a few tips on getting the right talent at the right time. This is the third article in a series in BayBioNotes.
11.11.09
Roadmap for growth: finance infrastructure nuts and bolts for start-ups
In article 2 of a series in BayBioNotes, we describe the roadmap for building a solid accounting, finance and administrative infrastructure from pre-funding stage activities through an M&A, IPO or secondary offering.
11.06.09
Is your finance structure a house of cards?
We’re not trying to be drama queens, but we’ve seen companies delay IPOs, miss out on high valuations and face other disasters because they lacked a finance infrastructure roadmap. Find out how our Scalable Finance Architecture™ can help, and get a free poster.
10.09.09
Roadmap for growth: right resources, right systems, right time
Our gurus take a no-nonsense approach to building a finance architecture that will give your start-up what it takes to grow. This article is the first in a series running in BayBioNotes.
10.06.09
What’s rev rec all about, anyway?
September’s FASB rule changes for bundled products have furrowed the brow of many a finance exec in Silicon Valley. But never fear: RoseRyan senior accounting guru Kelley Wall explains it all for you in this concise report.
10.02.09
M&A targets should start their engines
Despite the recession, there is M&A activity—but now acquiring companies are being even pickier about their prospects’ finances. What’s a target company to do? Check out our M&A prep list of simple things to do now.
7.17.09
Want a piece of the ARRA stimulus funding?
Companies that want to take advantage of the federal American Recovery and Reinvestment Act can’t sit around with their hands in their pockets. To help, RoseRyan and the legal pros at Sonnenschein developed the Stimulus Accelerator Program. Learn more about the possibilities here.
5.23.09
Don’t panic: here’s the scoop on fair value accounting
The recent brouhaha over mark-to-market accounting is largely overblown, says RoseRyan technical consultant Kelley Wall. The FASB’s pronouncement is merely common sense. Here’s her advice.
3.16.09
How to kick butt on a budget
Your staff got smaller, but not your workload. Find out how we can help you contain finance costs without sacrificing quality or introducing unnecessary risk.
2.13.08
SEC guru breaks down FAS141R
Our SEC superstar Maureen Earley sums up everything you need to know in this two-page distillation of FAS141R. She covers the rules for transaction costs, restructuring, in-process R&D and contingencies.
